A053
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Lymphoma
A063
Single-arm, dose-finding pilot trial of single-agent bortezomib in patients with relapsed/refractory AIDS-associated Kaposi sarcoma with correlative assessments of KSHV and HIV
A064
Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma from Patients with Aggressive B-cell Lymphomas
A075
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk- Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkinâ??s Lymphoma
ACOSOGZ6051
A Phase III Prospective Randomized Trial Comparing Laparoscopic-assisted Resection Versus Open Resection for Rectal Cancer ACOSOG Z6051
ACRIN6685
ACRIN 6685: A Multicenter trial of FDG-PET/CT staging of head and neck cancer and its impact on the N0 neck surgical treatment in head and neck cancer patients
E1208
A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion E1208
E1305
A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer E1305
E1505
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB ( greater than 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) E1505
E1808
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features E1808
E1906
E1906 A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML)
E2108
E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
E2511
E2511 Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
E2607
A Phase II Trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Solar Melanomas E2607
E2809
E2809 Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy
E3108
E3108 A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen
E3F05
Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas E3F05
E4805
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma E4805
E5103
E5103 A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
ECALGB80802
Phase III Randomized Study of Sorafenib Plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) C80802
ECALGB90601
A Randomized double-blinded Phase III study comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin,and Placebo in patients with advanced Transitional Cell Carcinoma C90601
ENSABPB43
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy NSABP B43
ENSABPB47
NSABP B47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
ENSABPB49
NSABP B49 A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
EPACCT1
PACCT1 Program for the Assessment of Clinical Cancer Tests: Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial
ES0535
ES0535 A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
ES0805
S0805 Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL)
ES1001
S1001 A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)
ES1007
S1007 Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer
ES1117
A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) S1117
G0076HH
(GOG 0076HH)A Limited Access Phase I/II Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Velaparib )IND#77840, NSC#737664) In The Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
G0258
(G258) A RANDOMIZED PHASE III TRIAL OF CISPLATIN AND TUMOR VOLUME DIRECTED IRRADIATION FOLLOWED BY CARBOPLATIN AND PACLITAXEL VS. CARBOPLATIN AND PACLITAXEL FOR OPTIMALLY DEBULKED, ADVANCED ENDOMETRIAL CARCINOMA
G0264
(GOG 264) A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
G0265
(GOG 265) A PHASE II EVALUATION OF ADXS11-001 (NSC 752718, BB-IND#13,712) IN THE TREATMENT OF PERSISTENT OR RECURRENT SQUAMOUS OR NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX
G9923
G9923 A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination with Continuous or Intermittent ABT-888 and Bevacizumab in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
J05121
A randomized phase II trial of Interferon + GM-CSF versus K562/GM-CSF vaccination in CML patients achieving a complete cytogenetic response to frontline tyrosine kinase therapy
J0625
K562/GM-CSF Vaccination in Combination with Imatinib Mesylate as Booster for Chronic Myeloid Leukemia Patients Previously Vaccinated on Protocol J0345
J0647
Psychopharmacology of psilocybin in cancer patients
J0650
Multicenter Selective Lymphadenectomy Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node
J0656
A Phase I efficacy and safety study of HPV16-specific therapeutic DNA-Vaccinia vaccination in combination with topical imiquimod, in patients with HPV16+ high grade cervical dysplasia (CIN2/3)
J0658
A Phase I/II Study of MS 275 in Combination with 5-azacytidine in Patients with Recurrent Advanced Non-Small Cell Lung Cancer
J0676
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Anemia and Other Hemoglobinopathies
J0703
A Phase I/II Study of 131I-Tositumomab in Patients with Relapsed/Refractory Hodgkinâ??s Lymphoma
J0739
Treatment of Patients with Hepatic Neuroendocrine Metastases using Drug-Eluting Bead Embolization
J0783
A Phase 1 Study of ABT-888 in Combination with Topotecan plus Carboplatin for Relapsed and Refractory Acute Leukemias and High-Risk Myelodyplasias and Myeloproliferative Disorders
J0810
A randomized three-arm, neoadjuvant and adjuvant, feasibility and toxicity study of a GM-CSF secreting allogeneic pancreatic cancer vaccine administered either alone, or in combination with either a single intravenous dose, or daily metronomic oral doses of cyclophosphamide for the treatment of patients with surgically resected adenocarcinoma of the pancreas
J08101
A Phase I/II Study of Dasatinib, Cetuximab and Radiation with or Without Cisplatin in Locally Advanced Squamous Cell Carcinoma of Head and Neck (HNSCC)
J08106
DEFIBROTIDE FOR PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD): A TREATMENT IND STUDY (UNDER CFR 312.34)
J08113
A phase 1, Open-label, Multicenter, multidose, Dose-escalation Study of BMS-936558/MDX-1106 in Subjects with Selected Advance or Recurrent Malignancies
J08126
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of AZD0530, a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung
J08130
Cytokine Expression During Radiation Therapy for Breast Cancer
J08135
A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb 004, a Humanized Monoclonal Antibody, in Subjects with Solid Tumors
J0820
A Phase II Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched Bone Marrow for Patients with Hematologic Malignancies
J0841
Phase I/II study of high dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor entinostat in patients with metastatic renal cell carcinoma.
J0859
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
J0866
A Pilot Study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)
J0867
Exploration and estimation of intratumoral concentration and activity of lapatinib in vivo in vestibular schwannomas.
J0874
A Phase I study of the mTOR inhibitor Temsirolimus in combination with the HDAC inhibitor Vorinostat in patients with metastatic prostate cancer .
J0882
Protocol Title: Phase II trial of High Dose Lenalidomide in Patients with MDS and AML with Trilineage Dysplasia (AML-TLD)
J0896
Percutaneously-Placed Continuous Flow Bupivacaine Pain Pumps to Decrease Post-operative Pain Following Mastectomy with Immediate Reconstruction
J09104
A Randomized Phase II Study of Rituximab with ABVD versus Standard ABVD for Patients with Advanced-Stage Classical Hodgkin Lymphoma with Poor Risk Features (IPS Score greater than 2)
J09108
The Clinical, Radiologic, Pathologic and Molecular Marker Characteristics of Premalignant and Malignant Pancreatic Cysts (The PCyst1 Study)
J09111
Imaging of Viral Thymidine Kinase Activity in EBV-Associated and KSHV-Associated Malignancies
J09112
A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995, IND#61198) plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in Adults with Relapsed and Refractory Disease
J09120
In Vivo Endomicroscopy (EM) for Improved Diagnosis of Barrett�??s Esophagus (BE) and Associated Neoplasia: A Multicenter Randomized Controlled Trial of Diagnostic Yield and Clinical Impact
J09121
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men with Castration Resistant Prostate Cancer
J09143
A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL, POETIC and ITCC T2008-002
J0915
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Advanced Solid Tumors.
J0918
''A Phase 1, Open-label, Multicenter, Dose-escalation, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors''.
J0937
Ultrasound-Guided Navigation in Robot-Assisted Laparoscopic Radical Prostatectomy
J0940
An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis Or Early Intervention with Pleurx Catheters in Patients with Malignant Ascites
J0941
Phase II trial of nonmyeloablative allogeneic BMT for B-cell lymphomas with post-transplantation cyclophosphamide and rituximab and optimized donor selection
J0947
J0947, A Randomized, Open-Label Comparative Study of Combination Therapy with Cyclophosphamide and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine With or Without Trastuzumab for the Treatment of Metastatic Breast Cancer that Does NOT Over-express HER-2/neu
J0963
Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients with Advanced Soft Tissue and Bone Sarcomas
J0964
Pancreaticoduodenectomy With or Without Braun Enteroenterostomy: Comparison of Postoperative Pancreatic Fistula and Delayed Gastric Emptying.
J0968
Expanded Access Protocol Safety and Efficacy of Varicella Zoster Immune Globulin (Human) (VariZIGâ?¢) in Patients At-Risk of Varicella Infection
J0977
Phase II study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer
J0988
"A Phase I/II Study of Treatment De-Intensification in Favorable Squamous Cell Carcinoma of the Oropharynx"
J1006
A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone, and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease
J10100
A Prospective Trial of Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Glioblastoma Multiforme
J10104
Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment with Topical Tretinoin
J10109
A Multicenter Phase I Study of TCD-717 Given by 4-Hour Intravenous Infusion in Patients with Advanced Solid Tumors
J10120
A phase I/II study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway and adult patients with recurrent or refractory medulloblastoma
J10122
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination with the MEK Inhibitor GSK1120212 in Subjects with BRAF Mutant Metastatic Melanoma
J10126
Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy with Bortezomib Combined with Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma
J1013
A Phase II Study of Gemcitabine and nab-Paclitaxel in Combination with GDC-0449 (Hedgehog Inhibitor) in Patients with Previously Untreated Metastatic Adenocarcionoma of the Pancreas
J10130
A Phase 2 Study of Paclitaxel with Cisplatin vs Fluoropyrimidine with a Platinum Agent for NeoadjuvantTherapy in Operable Esophageal Cancer Based on CHFR Methylation Status in Diagnostic Biopsies
J10140
Patient-donor vaccination in the context of allogeneic BMT incorporating high-dose posttransplantation cyclophosphamide
J1026
Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus
J1031
High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients (BMT CTN 0803- A071)
J1037
Randomized Phase II Trial Of Adjuvant Combined Epigenetic Therapy With 5-Azacitidine And Entinostat In Resected Stage I Non-Small Cell Lung Cancer Versus Standard Care
J1048
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects with Advanced Prostate Cancer.
J1051
A Phase 1 Study of the PARP Inhibitor ABT-888 in Combination with Temozolomide in Acute Leukemias.
J1055
Reduced intensity, partially HLA mismatched allogeneic BMT for hematologic malignancies using donors other than first-degree relatives
J1057
Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFBC PSMA based PET in Patients with Advanced Prostate Cancer
J1060
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia
J1066
A phase I/IIa study of safety and efficacy of Alpharadin® with docetaxel in patients with bone metastases from castration-resistant prostate cancer
J1067
A Phase 1b Study of GDC-0449 following Autologous Transplantation in Patients with High Risk First Remission or Relapsed Multiple Myeloma
J1070
A Randomized Phase I/II Trial of ICM (Irinotecan, Cisplatin, Mitomycin C) with or without AZD2281 (OLAPARIB) in Patients with Advanced Pancreatic Cancer
J1071
Intra-arterial chemotherapy for the treatment of intraocular retinoblastoma
J1074
A Phase II Trial to Determine the Effect of Imetelstat (GRN163L) on Patients with Previously Treated Multiple Myeloma (CP14B013)
J1093
A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination with 5-Azacytidine (5AC, NSC 102816) in Elderly Patients with Acute Myeloid Leukemia (AML)
J1097
A phase I study of Veliparib (ABT888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid tumor malignancies with peritoneal carcinomatosis.
J1099
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy
J1101
Randomized Phase II Trial of timed Sequential Therapy (TST) with Alvocidib (Flavopiridol), ara-C and mitoxantrone (FLAM) vs. "7+3" for Adults age 70 and Under with Newly Diagnosed Acute Myelogenous Leukemia (AML)
J1107
Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients with Advanced Breast Cancer
J11100
A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with Advanced Solid Tumors including Extensive Stage Small Cell Lung Cancer
J11102
A Phase I trial of oral 5-azacitidine in combination with romidepsin in advanced solid tumors, with an expansion cohort in non-small cell lung cancer
J11105
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction
J11106
A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in First-Line or in Switch Maintenance in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).
J11107
PHASE 2, multi-center, open-label investigation of HSPPC-96 vaccine with temozolomide in patients with newly diagnosed Glioblastoma Multiforme
J11110
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer (M12-895)
J11114
A Multicenter Access and Distribution Protocol for unlicensed cryopreserved Cord Blood Units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
J11116
A Pilot Study of Sorafenib in Patients with Acute Myeloid Leukemia as Peri-Transplant Remission Maintenance
J1112
A FEASIBILITY AND TOXICITY STUDY OF A GM-CSF SECRETING ALLOGENEIC MELANOMA VACCINE ADMINISTERED ALONE OR IN COMBINATION WITH CYCLOPHOSPHAMIDE IN SUBJECTS WITH SURGICALLY RESECTED AT-RISK MELANOMA
J11120
A phase II trial of low dose fractionated radiation therapy as a chemo-potentiator of salvage temozolomide for recurrent glioblastoma multiforme
J11121
A Phase Ib, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination with GDC-0941 When Administered in Patients with Locally advanced or Metastatic Solid Tumors. (Protocol MEK4752g)
J11125
J11125 Phase II Study of Gemcitabine/Taxotere/Xeloda (GTX) in combination with Cisplatin in Subjects with Metastatic Pancreatic Cancer
J11126
A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMab) In Combination With Tarceva (Erlotinib) In Patients With Met Diagnosticâ??Positive Nonâ??Small Cell Lung Cancer (NSCLC) Who Have Received Standard Chemotherapy For Advanced Or Metastatic Disease
J11129
A Phase I Clinical Trial Assessing the Safety and Feasibility of Administration of pNGVL4a-CRT/E7(detox) DNA Vaccine using the Intramuscular TriGridTM Delivery System in Combination with Cyclophosphamide in HPV-16 Associated Head and Neck Cancer Patients
J11149
(DFCI IRB 09-293) Phase I/II study of cediranib and olaparib in combination for treatment of recurrent papillary-serous ovarian, fallopian tube, or peritoneal cancer or for treatment of recurrent triple-negative breast cancer.
J1115
Administration of an Allogeneic Myeloma GM-CSF Vaccine in Conjunction with a Lenalidomide Containing Regimen in Myeloma Patients with Near Complete Remission.
J11151
A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration resistant prostate cancer
J11155
Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer
J11158
A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL
J11159
A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies (BMT CTN 1101)
J11162
Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas
J11164
Intra-arterial chemotherapy for the treatment of progressive diffuse intrinsic pontine gliomas (DIPG).
J1118
A Phase III, Multi-Center, Randomized, Controlled Study to Assess theEfficacy and Safety of ON 01910.Na Administered as a 72-Hour ContinuousIntravenous Infusion Every Other Week in Myelodysplastic SyndromePatients with Excess Blasts Relapsing After, or Refractory to, or Intolerantto Azacitidine or Decitabine
J1121
An Open-Label, Randomised, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of AT13387, either as Monotherapy or in Combination with Imatinib, in Patients with Unresectable and/or Metastatic Malignant GIST whose Tumour has Progressed Following Treatment with a Maximum of Three Tyrosine Kinase Inhibitors
J1123
A Phase I Study of AC220 (A2689) in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
J1124
A Phase II Study Of The Selective BRAF Kinase Inhibitor GSK2118436 In Subjects With Advanced Non-Small Cell Lung Cancer And BRAF Mutations
J1126
Phase II placebo-controlled study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7) DNA vaccine delivered IM followed by electroporation (EP) with Cellectra(R)-5P for the treatment of biopsy-proven CIN2/3 or CIN3 with documented HPV 16 or 18
J1129
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer
J1130
J1130, Phase 1b/2 Safety and Feasibility of Gemcitabine in combination with LDE-225 as Neoadjuvant Therapy in Patients with Borderline Resectable Pancreatic Adenocarcinoma.
J1137
An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors
J1138
A Phase 1, Open-Label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia and Selected B-cell Malignancies
J1141
Genome Wide Admixture for Multiple Myeloma in Africian Americans. (Africian-American MM GWAS)
J1144
A Phase 2 Randomized Open-Label Study Of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy In Previously Treated KRAS Mutation Positive Subjects With Locally Advanced Or Metastatic Nonâ??Small Cell Lung Cancer.
J1146
Efficacy and Safety of oral Kanglaite (KLTc) Gelcap in Men with Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc Gelcap (3 or 6 capsules four times/day) on Prostate Specific Antigen (PSA) Doubling Time Among Men with Rising PSA Levels after Definitive Local Therapy for Prostate Cancer
J1149
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine (with Cyclophosphamide) Alone or Followed by CRS-207 in Adults with Metastatic Pancreatic Adenocarcinoma
J1151
Shortened-duration tacrolimus following nonmyeloablative, related donor BMT with high-dose posttransplantation cyclophosphamide
J1152
Allogeneic Hematopoietic Cell Transplant for Hematologic Cancers and Myelodysplastic Syndrome in HIV-Infected Individuals
J1154
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC 1121B) Drug Product or IMC 18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
J1156
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen.
J1161
Phase I/II study of safety and efficacy of Muscadine Plus (MPX) in men with prostate cancer: A randomized, double-blind, placebo-controlled study of the effects of two doses of MPX capsule on rising prostate-specific antigen in men following initial therapy for prostate cancer
J1162
A phase I study determining the safety and tolerability of combination therapy with Pazopanib, a VEGFR/PDGFR/Raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer.
J1164
A Randomized Controlled Study of YONDELIS (Trabectedin) or Darcarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma
J1165
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Flt3-ITD positive Acute Myeloid Leukemia
J1178
LCH115397: A Phase 2a, Open Label, Multicenter Study to Assess the Efficacy and Safety of the Oral AKT Inhibitor GSK2110183 in Subjects with Langerhans Cell Histiocytosis
J1181
A RANDOMIZED, PHASE 2, OPEN-LABEL STUDY EVALUATING DN24-02 AS ADJUVANT THERAPY IN SUBJECTS WITH HIGH RISK HER2+ UROTHELIAL CARCINOMA
J1188
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Previously Untreated Advanced/Metastatic Pulmonary Adenocarcinoma
J1191
Evaluation of PSMA-based PET as an imaging biomarker of primary prostate cancer
J1192
A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
J1194
Phase I study of Mebendazole in Newly Diagnosed High-Grade gliomas
J1195
A Phase I Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination with Chemotherapy in Subjects with Refractory or Recurrent Acute Myelogenous Leukemia (Protocol No. P07649 005))
J1203
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study To Evaluate The Efficacy And Safety Of Afatinib (BIBW 2992) As Adjuvant Therapy After Chemo-Radiotherapy In Primary Unresected Patients With Stage III, IVa, Or IVb Loco-Regionally Advanced Head And Neck Squamous Cell Carcinoma.
J1207
Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol and daily genistein (G-2535) versus placebo in men with early stage prostate cancer undergoing prostatectomy
J1209
A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy
J1210
A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy (EPOCH)
J12102
An Exploratory Study of the Biologic Effects of BMS-936558 (Anti-PD1 Monoclonal Antibody) Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)
J12103
A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT 888 For Patients With Metastatic Castration-Resistant Prostate Cancer (NCI# 9012)
J12104
A Phase 2, Randomized Study to Assess the Safety and Anti-Cytomegalovirus (CMV) Activity of Different Doses of Maribavir for Treatment of CMV Infections that are Resistant or Refractory to Treatment with Ganciclovir/Valganciclovir or Foscarnet in Transplant Recipients
J12106
A phase II trial of partially HLA-mismatched (HLA-haploidentical) bone marrow transplantation for high-risk solid tumors.
J12108
A Randomized Open Label Phase II Study Of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone In The Treatment Of Patients With Persistent Or Relapsed Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma
J12109
(INCB 24360-210) A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects with Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission with First-Line Chemotherapy
J12111
A Phase 2 Study of the mTOR Inhibitor Everolimus in Combination with Bevacizumab in Patients with Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors
J12115
Lipiodol as an imaging biomarker of tumor necrosis after transcatheter chemoembolization therapy in patients with primary and metastatic liver cancer
J12117
A phase Ib/II, multicenter, open-label, dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600 â?? dependent advanced solid tumors
J12121
A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands
J12125
Phase II Trial to Evaluate Benefit of Early Switch from first-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the opposite sequence, exploring molecular markers and mechanisms of taxane resistance in men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have not received prior chemotherapy
J12127
A Phase II Trial of Hippocampal-Sparing Prophylactic Cranial Irradiation (PCI) for Small Cell Lung Cancer (SCLC)
J12130
A Registry for Patients Treated on the Clinical Trial TAX3503 (A randomized, open label, multicenter, phase III, 2 arm study of androgen deprivation with leuprolide, +/- docetaxel for clinically asymptomatic prostate cancer subjects with a rising PSA following definitive local therapy).
J12133
Phase II Study of Post-Operative Stereotactic Radiosurgery for Solid Tumor Spine Metastases
J1214
A multi-institutional open label, trial evaluating the efficacy of Gemcitabine and Docetaxel in patients with relapsed or refractory metastatic colorectal adenocarcinoma with methylated CHFR and/or microsatellite instability phenotype
J1217
A Multicenter Phase 2 Study of the Brutonâ??s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma
J1220
A Phase I/II Pharmacodynamic Study of Hydroxychloroquine in Combination with Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer.
J1224
Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
J1225
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients with Relapsed Small Cell Lung Cancer (SCLC).
J1228
A Trial of maintenance Rituximab with mTor inhibition after High-dose Consolidative Therapy in CD20+, B-cell Lymphomas and Hodgkin�??s Lymphoma
J1230
A Randomized Phase II Study of SUBATM-itraconazole with Cisplatin/Gemcitabine in Patients with Previously Untreated Metastatic Squamous Non-Small Cell Lung Cancer
J1231
T2009-003 A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL
J1232
Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1α (HIF-1α) Expression & Downstream Targets in Breast Cancer: DIG-HIF1 Pharmacodynamic Trial
J1239
A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse
J1244
A Phase 1b/2 Randomized Study of MEDI-573 in Combination with an Aromatase Inhibitor (AI) Versus AI Alone in Women with Metastatic Breast Cancer (MBC)
J1248
A Phase II Study Investigating CHFR Methylation Status As A Biomarker For Taxane Sensitivity Using Modified Docetaxel, Cisplatin and 5 Flourouracil In Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer.
J1253
A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with BMS-936558 (Anti-PD-1) in Subjects with Advanced or Metastatic Solid Tumors
J1256
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS 936558) in Subjects with Relapsed or Refractory Hematologic Malignancy
J1259
A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 with Fulvestrant, in Postmenopausal Women with Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer which Progressed on or After Aromatase Inhibitor Treatment
J1260
A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM
J1261
An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (asparaginase Erwinia chrysanthemi) Following Allergy to Native E. Coli Asparaginase (Elspar® or Kidrolase®), Pegaspargase (Oncaspar®) or Calaspargase pegol (EZN-2285) in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma
J1262
Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies: A Pilot/Feasibility Study
J1263
An Open-label Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator�??s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
J1265
A neoadjuvant immunologic study of androgen deprivation therapy combined with a GM-CSFâ??secreting allogeneic prostate cancer vaccine and low-dose cyclophosphamide in men with high-risk localized prostate cancer undergoing radical prostatectomy
J1266
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed By Standard Chemoradiation In HPV Negative Locally Advanced Stage III/IVa/IVb HNSCC.
J1267
An Open-label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC).
J1269
A Phase I Trial of Dinaciclib (SCH727965) and MK2206 in Metastatic Pancreatic Cancer with an Expansion Cohort in Advanced Pancreatic Cancer
J1271
A Randomized Three Arm Phase II Study of (1) Everolimus, (2)Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
J1273
Pilot Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable, Locally Recurrent Pancreatic or Periampullary Adenocarcinoma
J1274
A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma
J1275
A Phase I and Pharmacodynamic Trial of Timed Sequential Administration of the Cyclin Dependent Kinase 4/6 Inhibitor PD 0332991 Followed by Cytarabine plus Mitoxantrone for Adults with Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasias
J1276
A Phase 1 Study of Ipilimumab in relapsed and refractory high risk myelodysplastic syndrome and acute myeloid leukemia with minimal residual disease
J1280
J1280, A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
J1281
J1281, A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
J1282
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination with Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors
J1283
A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) with Pazopanib (P) or Gemcitabine (G) with Docetaxel (T) in Previously Treated Subjects with Advanced Soft Tissue Sarcoma
J1286
Long-Term Follow-Up Study of Patients who were Treated with Lethally-Irradiated GM-CSFâ??Transduced Allogeneic Prostate Cancer Cell Vaccine (Prostate GVAX)
J1287
A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
J1288
An Open-Label Randomized Phase III Trial of BMS-936558 versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC).
J1291
A Randomized, Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
J1293
Cellular and molecular characterization of the immune response before and after immunization with the seasonal influenza vaccine in adult patients who have completed treatment for acute myeloid leukemia.
J1294
Assessing The Impact On Chemotherapy Decision Making While Utilizing The NCCN Guidelines When The Cost Of Each Regimen Is Provided To Prescribers And Patients.
J1298
A Phase II Study of Bipolar Androgen-based Therapy for Men with Androgen Ablation Naïve Recurrent Prostate Cancer
J1304
Presenting Patient-Reported Outcomes Data to Improve Patient and Clinician Understanding and Use
N1101
A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment
PAALL0232
AALL0232 High Risk B-Precursor Acute Lymphoblastic Leukemia
PAALL0434
Intensified Methotrexate, Nelarabine (Compound 506U78; IND# 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
PAALL05B1
A Children?s Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
PAALL0631
A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431; NSC#617807)
PAALL07P1
A Phase II Pilot Trial of Bortezomib (PS-341, Velcadeï¿¢, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
PAALL07P2
AALL07P2 Pharmacology and Toxicity of Erwinia Asparaginase (Erwinase®; Crisantaspase; IND 290) Following Allergy to PEG-Asparaginase in Treatment of Children with Acute Lymphoblastic Leukemia (ALL)
PAALL0932
Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
PAALL1122
CA180-372 ( COG Protocol AALL1122): A Phase 2 Multi-Center Historically - Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
PAALL1131
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
PAAML1031
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.
PACNS02B3
A COG Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
PACNS0331
ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
PACNS0332
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
PACNS0333
Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation
PACNS0334
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children less than 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy without Methotrexate
PACNS0821
Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
PACNS0822
A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND# 7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas
PACNS0831
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
PACNS1123
Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
PADVL0921
A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias
PADVL1011
ADVL1011, A Phase 1 Study of JAK Inhibition (INCB018424) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms
PAEWS1031
A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
PAHOD04B1
Hodgkin Disease (HD) Banking Study
PANBL0032
ANBL0032 Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
PANHL04B1
Rare and Cutaneous Non-Hodgkin Lymphoma Registry
PAREN03B2
Renal Tumors Classification, Biology, and Banking Study
PAREN0532
Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor
PARST08P1
A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC # 742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma
PARST0921
A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma
PASCT0631-2
COG ASCT0631/PBMTC STC051 A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source in Matched Sibling Donor Transplantation
POETIC1003
POETIC10-03: A Phase I Study Using Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
R0926
R0926 A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
R0937
R0937 Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
SUBENSABPB47
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer. NSABP B47
TBCRC022
A Phase II Trial of HKI-272 (Neratinib) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases
TBCRC023
A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab, with or without Endocrine Therapy for 12 weeks vs. 24 weeks in patients with HER2 Overexpressing Breast Cancer
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts